Navigation Links
Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Date:5/17/2011

ex (NIH-CPSI) scale, which measures symptoms and impact on quality of life (-12.1 +/- 9.3 vs. -8.5 +/- 7.2; P=0.0224).  Statistically significant treatment effects were seen with RAPAFLO(R) 4 mg on the NIH-CPSI scale evaluating urinary symptoms (–2.2 +/- 2.7 vs –1.3 +/- 3.0; P=.0102). Decreases in NIH-CPSI scores with RAPAFLO(R) 8 mg did not provide any additional therapeutic benefit compared to the 4 mg dose.  

In addition, patients treated with RAPAFLO(R) 4 mg showed significantly better results relative to placebo on the physical component of another widely accepted evaluation tool, the 12-Item Short Form Health Survey (SF-12) developed to study patients with chronic conditions (4.2 +/- 8.1 vs 1.7 +/- 9.0; P=.049). In a global response assessment (GRA), 56 percent of patients treated with RAPAFLO(R) 4 mg versus 29 percent of patients receiving placebo reported moderate or marked improvement (P= 0.0069). An increase in dose to 8 mg resulted in no incremental increased effect.

Safety Findings

Overall, one in three (33.1%) of men in the study experienced a treatment-related adverse event (AE).  The incidences of drug-related AEs were similar for RAPAFLO(R) 4 mg and placebo, and included: dizziness (1.9%, 4 mg; 8.9%, 8 mg; 7.4%, placebo);  headache (0, 4 mg; 4.4%, 8 mg; 1.9%, placebo); nasal congestion (3.8%, 4 mg; 6.7%, 8 mg; 0, placebo); and decreased libido (1.9%, 4 mg; 2.2%, 8 mg; 1.9%, placebo).  The most common adverse event was retrograde ejaculation.  More men treated with RAPAFLO(R) versus placebo experienced retrograde ejaculation (26.9%, 4 mg; 40%, 8 mg; 1.9%, placebo).  Retrograde ejaculation, or an orgasm with reduced semen, is an expected and reversible effect of selective alpha blockers and thought to be a direct reflection of the product's selective binding properties.  Discontinuation rates due to a drug-related adverse event were 5.8 percent f
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Watson Confirms Renvela® Patent Challenge
2. Delaware Court Rules That Watson Does Not Infringe Patent Related to Generic Version of Concerta(R) and Declares Patent Invalid
3. Watsons GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder
4. Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights
5. Inovio Pharmaceuticals Reports Long-Term Immune Responses from Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
6. Vanda Pharmaceuticals Reports First Quarter 2011 Results
7. MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results
8. Anadys Pharmaceuticals to Report First Quarter 2011 Financial Results
9. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
10. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2011 Financial Results
11. Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22. 2015  Varian Medical Systems (NYSE: ... been honored for its commitment to sustainability with inclusion on ... is the highest ranked healthcare equipment company among the Corporate ... the World Economic Forum at Davos, Switzerland ...
(Date:1/22/2015)... N.J. , Jan. 22, 2015  Derma Sciences, ... regeneration company focused on advanced wound care, announces ... placental tissues, have been added to the Premier, ... increases the opportunity for the AMNIOEXCEL® and AMNIOMATRIX® ...
(Date:12/24/2014)... SPRING, Md. , Dec. 24, 2014  United Therapeutics ... Medtronic, Inc. (NYSE: MDT ) has submitted ... Drug Administration (FDA) for the use of Medtronic,s SynchroMed ... newly developed catheter) for use with United Therapeutics, Remodulin ...
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   ... disease, announced today that the Company closed its ... Investment Management, Jack W. Schuler , Birchview ... were $10.5 million, before offering expenses.  The proceeds ...
Breaking Biology Technology:Varian Honored Among World's 100 Most Sustainable Corporations 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... HGS product sales achieved with delivery of ABthrax(TM) to U.S. ... cash balance of $397 million as of March 31, up ... for second Phase 3 trial of Albuferon (R) ... fall 2009 - - Initiation of Syncria (R) ...
... RICHMOND, Calif., April 29 Sangamo BioSciences, Inc. ... success of its zinc finger DNA-binding protein (ZFP) ... Nature by licensing partner Dow AgroSciences ... technology for the efficient generation of maize plants ...
... , ... Austin, Texas (PRWEB) April 29, 2009 -- ... storing and distributing content, today announced the release of CAStor 3.0, ... virtual CAStor nodes in a single, physical server chassis. CAStor Cluster ...
Cached Biology Technology:Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments 2Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments 3Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments 4Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments 5Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments 6Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments 7Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments 8Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments 9Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments 10Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species 2Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species 3Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species 4Caringo Delivers Storage Cluster in a Box with CAStor 3.0 2
(Date:12/11/2014)... Dec. 10, 2014  That blood pressure plays a role in ... – the medical term for high blood pressure – was ... the inflatable cuff that,s used in measuring blood pressure was ... nothing new about hypertension, its triggers and its effects. In ...
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here before: you desperately ... your password, site key or the answer to your secret question. ... Today, Hoyos Labs , a digital infrastructure security ... end to the frustration that comes with usernames, passwords and PINs ...
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest Baptist ... building for its School of Medicine. Funding for this $50 ... that will be publicly launched next summer. ... 60 series R.J. Reynolds Tobacco Company complex, adjacent to 525@vine ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... flu viruses that infect birds and humans, a discovery that ... and aid in the development of vaccines against a deadly ... to infect humans depends on whether it can bind to ... respiratory cells. Now that we know what to look ...
... Diego has become the first campus on the West Coast ... voluntary, legally binding trading system to reduce emissions of greenhouse ... the nation to join the climate exchange. Joining the ... conserve energy and reduce greenhouse gases (GHG). Trading in GHG ...
... Ohio State University will battle for the BCS National ... but if the game was held in the Louisiana ... Louisianas wetlands are being lost at the rate of ... against this rapid destruction, the two universities joined forces ...
Cached Biology News:MIT finds key to avian flu in humans 2MIT finds key to avian flu in humans 3UC San Diego begins trading greenhouse gas credits on Chicago Climate Exchange 2LSU and Ohio State battle on football field, collaborate in research field 2
For the quantitative determination of canine Interferon gamma,(IFN-γ) concentrations in cell culture supernates, serum and,plasma....
Request Info...
Homo sapiens olfactomedin 1, transcript variant 3...
Component of GELase™ Agarose Gel-Digesting Preparation. 1 ml of 50X Buffer is sufficient for replacing the buffer in at least 5 g of gel....
Biology Products: